TerminatedPhase 2NCT00267527
A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity
ConjuChem120 participantsDec 2005 to Sept 2006
Obesity · HIV Infections
Compare peptides
Compare two to four peptides side by side. Counts are exact.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog CJC-1295 (with DAC) | Natural peptide HGH (somatotropin) | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Natural peptide | |
| Area | Growth hormone axis | Growth hormone axis | |
| Evidence | |||
| Amount of evidence | 43 | 1,108 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 2 (2 in people) | 110 (108 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 1 | 358 · 32 active72 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Its most advanced trial is in phase 2. The FDA, the EMA and the other sources we use show no approval (as of 9 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | CJC-1295 (with DAC) | HGH (somatotropin) |
|---|---|---|
| Bone and jointMusculoskeletal | 11 | 12611511 |
| Growth hormone and IGF-1Endocrine and hormones |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Genotropin says: “Replacement in adults with adult-onset or childhood-onset GHD”
2716101
1069115 |
| Adverse eventsWhole body | 11 | 60582 |
|---|
| Body weightMetabolic and weight | 44 | 46415 |
|---|
| Receptor activity and mechanismPharmacology | 11 | 2626 |
|---|
| PharmacokineticsPharmacology | 7151 | 23320 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
CJC-1295 (with DAC) differs from Somatorelin, human GHRH(1-44) at 5 positions.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | CJC-1295 (with DAC) | HGH (somatotropin) |
|---|---|---|
| Growth hormone and IGF-1Endocrine and hormonesCompared as: value in the arm that got the peptide, in cm/year | No comparable result 3 randomized-trial results measure it in another way or another unit. | 9.78 cm/year Height velocity · somatropin at month 12 Dose studied: 0.24 mg/kg/week once daily12 monthsn = 2282022 |
| PharmacokineticsPharmacologyCompared as: value in the arm that got the peptide, in d | 5.8 to 8.1 d Half-life · CJC-1295 28 d and 49 d trialsn not reported2006 | No randomized trial result 23 results from other study designs. |
| Adverse eventsWhole bodyCompared as: value in the arm that got the peptide, in % | No comparable result 1 randomized-trial result measure it in another way or another unit. | 79.1% Treatment-emergent adverse events Dose studied: 0.24 mg/kg/week once daily12 monthsn = 2242022 |
No comparable result
3 randomized-trial results measure it in another way or another unit.
9.78 cm/year
Height velocity · somatropin at month 12
Dose studied: 0.24 mg/kg/week once daily12 monthsn = 2282022
5.8 to 8.1 d
Half-life · CJC-1295
28 d and 49 d trialsn not reported2006
No randomized trial result
23 results from other study designs.
No comparable result
1 randomized-trial result measure it in another way or another unit.
79.1%
Treatment-emergent adverse events
Dose studied: 0.24 mg/kg/week once daily12 monthsn = 2242022
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
1 trial · 1 stopped early · source ClinicalTrials.gov (opens in a new tab)
ConjuChem120 participantsDec 2005 to Sept 2006
Obesity · HIV Infections
Top 3 of 358 trials, ranked by phase, then posted results and enrollment: 2 completed · 1 stopped early · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S712 participantsJul 2007 to Dec 2008
Chronic Kidney Disease · End-Stage Renal Disease
EMD Serono326 participants28 May 2004 to 28 Sept 2005
HIV Infections · Lipodystrophy
Pfizer316 participantsDec 2006 to Aug 2012
Idiopathic Short Stature
72 more mention it but do not test it. They only measure it or name it in their text.